Obesity has recently been linked to mortality from the majority of cancers. The insulin/insulin-like growth factor (IGF) system may partly explain this effect. The metabolic syndrome, associated with hyperinsulinemia, may modulate this effect. Recent evidence supports the role of insulin and IGF-1 as important growth factors, acting through the tyrosine kinase growth factor cascade in enhancing tumor cell proliferation. In addition, the metabolic syndrome associated with a chronic inflammatory state and accompanying cytokine abnormalities may also contribute to tumor progression. Growing links between insulin and the etiology as well as prognosis in colon, prostate, pancreatic, and, particularly, breast cancer are reviewed. Of particular concern is the evidence that elevated IGF-1 may interfere with cancer therapy, adversely affecting prognosis. The role of insulin is of concern because of the increasing levels of obesity and the associated metabolic syndrome. Weight gain, through typical Western diet; limited levels of activity; and, more recently, stress-related changes in neuroendocrine function may lead to insulin resistance and hyperinsulinemia. The opportunity for a multidisciplinary approach involving nutrition, exercise, and stress reduction in an integrative setting may be crucial to limiting the insulin-resistant state and improving cancer outcomes.
A recent study from the American Cancer Society's Cancer Prevention II (CPII) prospective cohort of more than 900,000 men and women followed over 16 years revealed an important relationship between overweight and obesity and mortality from multiple malignancies. 1 Indeed, the majority of individual cancers as well as total cancer mortality were influenced by the presence of obesity. This study was preceded by a growing body of evidence [2] [3] [4] [5] linking both cancer etiology and prognosis to the obese state. Many explanations have been sought to explain this relationship, including the known effect on hormones, particularly the sex hormones, on tumor growth; the effect of overweight on the effectiveness in screening practices such as mammography; the differential health behaviors of overweight individuals; and even the potential for underdosing with chemotherapy in the obese patient.
Each of these explanations, while of potential import in selected cancers, fails to account for the broad effect in such a wide variety of tumor types. Both reproductive cancers, such as breast, endometrial, prostate, and ovarian cancers, and nonreproductive malignancies, including colon, pancreatic, gall bladder, kidney, liver, esophageal cancers, and non-Hodgkins lymphoma and myeloma are adversely affected by obesity.
An important consequence of obesity, the hyperinsulinemic state, may provide the most parsimonious explanation for this relationship. In addition to its importance in glucose homeostasis, insulin is a crucial hormone in anabolic processes involved in early growth and development. 6 It serves as an important growth factor, both directly through the insulin receptor and indirectly through its effect on the IGF/IGFR system on almost all cells. 7, 8 In this article, I will outline the relationship between obesity and the insulinresistant state and review the evidence linking a variety of cancers to obesity, with attention to insulin as the crucial mediator of this effect. I will focus particularly on breast cancer, providing evidence for the prognostic impact of the insulin/insulin-like growth factor (IGF) system, the mechanism of insulin's effect on breast cancer growth and progression, and its interactions with both hormonal treatment and chemotherapy. In addition, the development of hyperglycemia and insulin resistance as a frequent consequence of advanced malignancy will be reviewed.
The insulin-cancer relationship is particularly important to the integrative cancer practitioner. It provides a plausible biological basis for many integrative cancer therapies, including nutrition and exercise, and may provide the best explanation to date for the role of stress in cancer causation and progression. This is of increasing importance given the limited credence given to the use of mind-body approaches by most conventional physicians as an important adjunct to conventional cancer therapy. In addition, the emerging evidence for an obesity-insulin cancer connection may help reconcile the often conflicting As originally described by Himsworth, 18 obese, older patients in contrast to young, lean individuals have a reduction in insulin response to glucose infusion, consistent with insulin resistance. This fundamental observation led to the distinction between type 1 and type 2 diabetes mellitus, the latter characterized by insulin resistance rather than deficiency. In 1988, the entity, syndrome X, now termed the metabolic syndrome or the insulin resistance syndrome, was described by Gerald Reaven. 19 Initially a cluster of clinical and metabolic features, including hypertension, low HDL, hypertriglyceridemia, glucose intolerance with insulin resistance and hyperinsulinemia, and, more recently, abdominal/visceral obesity, it is now felt to represent a true clinical entity rather than a statistical association of varying features. 20 The metabolic syndrome has been closely linked to the development of frank diabetes 21 and is a significant risk factor for cardiovascular morbidity and mortality. [22] [23] [24] [25] More recently, Reaven noted, in a prospective study of nonobese males, an increased risk of cancer events occurred only in those individuals with increased insulin resistance, 26 reinforcing the growing evidence for an insulin-cancer connection.
The development of the metabolic syndrome has been linked to both increasing obesity and declining levels of physical activity, [27] [28] [29] [30] and its incidence has been rising in parallel with the growing obesity epidemic. 31 Disturbingly, there has been a rising incidence of both obesity and the metabolic syndrome in the developing world, as individuals acquire a more Western lifestyle, including diet and altered activity patterns. 32, 33 Numerous dietary factors have been shown to contribute to insulin resistance, including high-fat diets, particularly saturated, nonplant fats 34 mediated by direct fatty acid effects on adipocyte insulin resistance, increasing levels of omega-6 fats such as linoleic acid, and the high intake of concentrated (sucrose, fructose) and refined (high glycemic index) carbohydrates. 34, 35 Conversely, plant-based diets, with high fiber intake as well as high fish intake, associated with high omega-3 content, may increase insulin sensitivity and reduce risk of the metabolic syndrome. [36] [37] [38] [39] Similarly, recent studies using cluster analysis to assess dietary patterns 40, 41 have indicated that diets high in fruit, vegetables, and whole grains and low in red meat, processed foods (fast food), and soda are linked to lower weight (body mass index) and waist circumference, prime markers of the insulin-resistant state. Interestingly, there is growing evidence of the protective effect of increased dairy intake, perhaps mediated by calcium. [41] [42] [43] There is clear evidence linking physical activity, both work related and leisure-time related, to a reduced risk of developing the metabolic syndrome. This relationship exists across multiple ethnic populations 44 and appears to be proportionate to the level of activity and fitness. This may in part reflect an upregulation of components of the glucose transport system including GLUT-4 and insulin receptor substrate-1 45 as well as the increased lean body mass/body fat ratio. 46 While there are also complex genetic links to the insulin-resistant state as well as type 2 diabetes, their expression is strongly influenced by lifestyle-related environmental factors. It has been clearly demonstrated that intensive lifestyle intervention, with both dietary and exercise intervention, can modify insulin resistance 47 and reduce the subsequent risk of type 2 diabetes mellitus. 48 As noted, while obesity has been linked to insulin resistance, it is abdominal obesity and, more specifically, visceral adiposity that are most closely related to this state. 20, 49 While insulin resistance has been most closely associated with overall obesity as measured by body mass index (BMI) (weight[kg]/height [m] 2 ), there also exists an entity characterized by increased visceral fat, without overt obesity as defined by increased BMI, that is associated with insulin resistance. 50 This may be better reflected in the waist-hip ratio (WHR) or waist circumference. As a result, simple measures of overall weight may miss this nonobese at-risk population.
In addition to the known effects of diet and physical activity in the metabolic syndrome, there is growing evidence that chronic stress may lead to the development of abdominal and visceral obesity and insulin resistance. [51] [52] [53] Initial studies suggested a behavioral explanation, including altered dietary and activity patterns. More recent work indicates this is directly mediated by an alteration in the hypothalamic-pituitaryadrenal (HPA) axis, leading to an abnormal diurnal cortisol rhythm and increased visceral fat stores. 52, 53 This has important implications for the relationship between severe stress and cancer outcomes, with insulin serving as a potential metabolic mediator of tumor progression.
Insulin Resistance and Cancer Mechanisms
There are multiple mechanisms through which insulin resistance may affect the malignant state. Cancer is a multistep process reflecting acquired genetic alterations driving the progressive transformation process, from normal to preneoplastic to malignant cells. 54 The evolution of malignancy may additionally reflect the progression from an early, indolent cell population to a more aggressive state, accompanied by the acquisition of growth factor independence, resistance to programmed cell death, sustained angiogenesis, and invasive and metastatic potential. An increased fraction of tumor cells in the proliferative phase will enhance the chances of more rapid acquisition of crucial genetic changes, leading to earlier tumor progression and shortened survival. Insulin and the insulinresistant state may play a role both in the development of the neoplastic state and in the drive to this more malignant phenotype, what I describe as "phenotypic modulation."
Insulin, via activation of insulin receptors expressed ubiquitously in normal and neoplastic cells, may enhance the anabolic state necessary for cell growth, allowing sustained availability of substrates, including glucose and amino acids. In addition, both insulin and insulin-like growth factor-1 (IGF-1) increase sex hormone synthesis and reduce sex hormone-binding globulin levels, leading to elevated levels of estrogen and other hormonal tumor promoters. 55 More important, both insulin and IGF-1 activate the important tyrosine kinase growth receptor pathway, insulin receptor (IR) and IGF-1 receptor (IFG-1R), respectively, as well as the hybrid IGF-1/insulin receptor, all of which are expressed at higher levels in malignant cells [56] [57] [58] [59] and resistant to downregulation typical of receptors in nonmalignant cells exposed to insulin. 60 Activation of these receptors results in upregulation of insulin response substrate-1 (IRS-1), leading to downstream activation of the mitogen-activated protein (MAP) kinase pathway and the phosphoinositol-3 kinase/Akt (PI3K-Akt) pathway. The MAP kinase-Ras-Raf cascade is centrally important in driving tumor cell proliferation. PI3K-Akt signaling is involved in anchorage-independent cell growth 61 and cell cycle entry at the G1/S transition 62 and is an important survival signal inhibiting apoptosis. 54, 63 In addition to the direct effects of insulin at the IR, insulin inhibits hepatic synthesis of both IGFBP-1 and IGFBP-2, leading to an increase in free IGF-1 and enhanced signaling via the IGF1-receptor. 64 An important characteristic of the insulin-resistant state is the presence of a systemic, low-grade inflammatory state, [65] [66] [67] [68] [69] associated with elevations in interleukin-6 (IL-6) and C-reactive protein (C-RP), tumor necrosis factor-α, fibrinogen, and cell adhesion molecules ICAM-1 and VCAM-1, 69 believed to be at least partly responsible for the increased risk of vascular disease. The level of these inflammatory mediators has been shown to correlate with the degree of hyperinsulinemia as well as other markers of the insulin-resistant state such as postprandial hyperglycemia. Increasing evidence has pointed recently to the potential role of the inflammatory state in the malignant process, including an increased stimulus to tumor cell proliferation as well as paracrine-related effects mediated by inflammatory cell-related cytokines, such as increased angiogenesis. 70 Intriguingly, the same markers of the chronic inflammatory state, that is, IL-6 and C-RP, have been shown to adversely affect survival in multiple cancers, including colon, breast, esophageal, pancreatic, renal cell, head and neck, ovarian, lung carcinoma, myeloma, and non-Hodgkins lymphoma, [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] as well as advanced cancer in general. 83 In the majority of these series, the prognostic impact of the inflammatory state was independent of known prognostic factors such as stage, grade, and comorbid conditions. While advanced cancer associated with elevations in these mediators is often accompanied by weight loss, an adverse factor in survival, this is not true of early-stage cancers. It is possible that the obesity/insulin resistance-related activation of chronic inflammation may also enhance tumor progression and shorten survival through these mechanisms (increased proliferation, reduced apoptotic cell death, increased angiogenesis, etc), in addition to direct IR/IGF-1R activation. Interestingly, the spectrum of cancers affected by obesity in the CPII study 1 is very similar to the cancers for which prognosis is associated with the inflammatory state noted above.
Depression, a frequent psychological manifestation of stress and common in the cancer patient, has also been linked to an up-regulation of inflammatory cytokines including IL-6 and C-RP. 84, 85 Obesity, Insulin, and Selected Cancers Colon Cancer Epidemiologic evidence has linked a variety of factors, typified by the Western lifestyle, to the development of colon cancer, including reduced folate and calcium; increased saturated fat, particularly red meat; increased alcohol; and, most prominently, decreased dietary fiber. Despite the persuasive and long-standing evidence from large ecological studies connecting high-fiber diets to colon cancer, recent intervention trials have failed to show an effect in polyp prevention,
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the initial preneoplastic phase in colon carcinogenesis. 11, 12 Numerous studies have suggested an association between obesity and colon carcinoma. 1, 86, 87 Conversely, increasing physical activity is consistently linked to lower risks of colon cancer [87] [88] [89] [90] [91] and may obviate the adverse effect of obesity. 92 The common mediator of this effect appears to be insulin resistance and hyperinsulinemia. Associations have been noted with high glycemic diets, 93 postprandial hyperglycemia, 94 elevated HgbA1c levels, 95 and type 2 diabetes mellitus 96, 97 and colon cancer. Insulin and IGF-1 levels are correlated with elevated risk, and there is increased expression of both insulin receptor and IGF-1 receptors in colonic cancer cells. In animal models of colon carcinogenesis utilizing chemical carcinogen (azoxymethane) initiation of aberrant crypt foci, modulation of insulin resistance through high-fat diet and high-glycemic foods enhanced tumor promotion, as did the direct infusion of insulin. [98] [99] [100] [101] In contrast, diets with increased n-3 fatty acids and caloric restriction reduced aberrant crypt foci growth associated with reduced insulin resistance. 101 Interestingly, in contrast to breast cancer, hormone replacement therapy (HRT) has been consistently associated with a decreased risk of colon cancer in women. A recent case-control study from western Washington confirmed the increased association of diabetes and colon cancer and suggested that diabetic women do not share the protective effect of HRT in nondiabetic women. They suggested this reduced risk with HRT was secondary to effects on insulin metabolism of exogenous estrogen, 102 obviated by the hyperinsulinemia associated with diabetes.
While the evidence favoring a role for insulin in colon carcinogenesis is compelling, there are also growing links between insulin and colon cancer mortality. Trevisan et al 103 in the Risk Factors and Life Expectancy Project, a pooling of numerous epidemiologic studies in Italy, analyzed individuals for the cluster of abnormalities associated with the metabolic syndrome. Those with hyperglycemia or the metabolic syndrome experienced a significant increase in colon cancer mortality (relative risk [RR],~2.9). Similarly, the Chicago Heart Association Detection Project noted an association between elevated postprandial glucose and insulin resistance with increased mortality from colon cancer. In a recent study of stage II and III colon cancer patients in a CALGB adjuvant chemotherapy trial, those with diabetes had a significantly reduced survival (6 vs 11.3 years) and a 21% increase in recurrence after adjustment for prognostic factors and treatment-related side effects. 104 As Giovannucci 87 has suggested, insulin resistance and the hyperinsulinemic state may be the crucial link between the epidemic of colon cancer in the late 20th century and the concurrent rise in sedentary lifestyles, altered dietary patterns, and obesity. It appears also that it may have an adverse effect on colon cancer outcomes as well.
Prostate Cancer
In contrast to colon cancer, prostate cancer risk has not been consistently associated with increased BMI. 105 However, numerous studies have implicated BMI/ obesity in increased prostate cancer mortality. In the 2 large American Cancer Society cohorts, CPI (1959) (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) and CPII (1982 CPII ( -1996 , obesity decreased survival from prostate cancer. 106 Similarly, in a large cohort of Swedish men, increased BMI was associated with increased prostate cancer death rates. 107 The failure of BMI to correlate with prostate cancer risk may obscure the more important relationship with adipose tissue distribution. A large National Cancer Institute (NCI) study 108 in China, in a relatively lean population, confirmed the absence of an association with BMI or weight. However, those men with an increased WHR (associated with abdominal/visceral obesity) had an almost 3-fold increase in prostate cancer. In a follow-up study, 109 measures of insulin resistance were obtained in the same population. Increasing insulin resistance correlated with increased risk at all levels of WHR. Those men with the highest tertile of insulin resistance and WHR had an 8-fold higher risk of developing prostate cancer. Numerous studies have implicated IGF-1 in prostate cancer risk. [110] [111] [112] In the large, prospective Physicians Health Study, 112 men with the highest quartile of IGF-1 had an RR of 4.3, compared to the lowest quartile, independent of BMI.
Obesity and insulin resistance also appear to be associated with adverse prognosis in prostate cancer. In a multiethnic population in San Diego of Asian, Caucasian, and black men, obesity was an independent predictor of Gleason grade and non-organconfined disease. 113 Similarly, a small cohort of black and white men revealed a significant association between BMI and pathologic stage. 114 IGF-1R is upregulated in prostate cancer and persists in metastatic disease. IGF-1 levels and IGF-1R expression are associated with increasing androgen independence. 115, 116 In a large follow-up study from Mt Sinai Hospital, 117 those men with the highest risk for recurrence (prostate specific antigen [PSA] > 15, Gleason grade > 7, positive seminal vesicle biopsy) had significantly higher serum insulin levels than low-to medium-risk men.
Dietary factors may interact through the insulin/ IGF pathway to influence prostate cancer progression. Dietary lycopene has been found to be one of the strongest factors in risk of prostate cancer, and in one small study, lycopene supplements for a short period prior to prostatectomy reduced PSA and margin positivity at the time of surgery. In a large case-control study in Athens, Greece, in 112 men on the effects of diet on the IGF system, only the intake of cooked tomatoes (rich in lycopene) was shown to be significantly inversely related to IGF-1 levels. 118 In a low-fat diet and exercise study among overweight men without prostate cancer, 119 both a short-term and a longterm intervention significantly lowered IGF-1 and increased IGFBP-1 levels, with much larger changes in the long-term group. Serum obtained after intervention substantially reduced growth and increased apoptosis in LNCaP tumor cells in vitro compared to preintervention serum.
Pancreatic Cancer
Pancreatic cancer has long been associated with tobacco use and diabetes mellitus. Until recently, the association with diabetes has been attributed to the adverse impact of tumor growth directly on pancreatic function. There is growing evidence implicating insulin resistance and diabetes in the etiology of pancreatic carcinoma.
Numerous studies have documented a positive association between pancreatic cancer and increased BMI as well as obesity. 1, [120] [121] [122] [123] Increased level of physical activity appears protective, particularly in overweight or obese patients. 122, 123 In the Physicians Follow-up Study/Nurses Health Study (NHS) cohort, 122 individuals with a BMI of greater than 30 kg/m 2 had an elevated risk of pancreatic cancer. Physical activity was inversely related to risk among individuals with a BMI greater than 25 kg/m 2 .
Both abnormal glucose tolerance and frank diabetes mellitus are increasingly recognized as etiologic factors with pancreatic cancer. In the American Cancer Society CPII prospective cohort, 123 a history of diabetes mellitus was significantly related to pancreatic cancer mortality, in both men and women, even when the diagnosis of diabetes preceded the cancer by many years. Similarly, in a large NCI case-control study on pancreatic cancer in 3 areas of the United States, 124 a significant positive trend was observed with increasing years of diabetes preceding the cancer diagnosis, with those diagnosed 10 years prior experiencing a 50% increase in risk. In a large prospective cohort study of individuals in 84 Chicago-area organizations over 25 years, insulin resistance, as measured by postload glucose levels, was associated with increasing pancreatic cancer risk, particularly in men. 120 In a cohort of women in the NHS, 125 a 53% increase in risk was noted among women with a high glycemic load intake, and a similar association was seen with fructose intake. This dietary trend was most apparent in the women with both a higher BMI and lower physical activity, with a combined risk of 267%.
Pancreatic cancer cells have an increased expression of both insulin and IGF-1 receptors. [126] [127] [128] Pancreatic cancer patients show an increase in IGF-1 and IGFBP levels accompanied by a dramatic increase in IGF-1R expression. 126 IGF-1R activation is associated with increased cell proliferation, invasiveness, and vascular endothelial growth factor expression, 128 as well as resistance to apoptosis, 129 mediated by both the MAPK and PI3K signaling pathways. Interestingly, cyclooxygenase 2 (COX-2) is highly expressed in pancreatic cancer cells, and COX-2 inhibitors exhibit modest antitumor activity, including growth inhibition and G1 arrest in the BxPC-3 pancreatic cell line. In this in vitro model, 130 IGF-1 was able to completely attenuate the celecoxib-induced apoptosis, associated with the increased activation of Akt. Conversely, in the PANC-1 in vitro pancreatic cell line, ascorbate stearate, a lipophilic ascorbic acid derivative, markedly inhibited cell growth and increased apoptosis, accompanied by a reduction in IGF-1R expression. 131 In several in vitro pancreatic cancer cell lines, 127 insulin induced cell growth in a concentration-and time-dependent manner, associated with an increase in glucose utilization, an effect that was substantially reversed by either MAPK or PI3K inhibitors. Insulin appeared to augment DNA synthesis through MAP kinase activation and glucose uptake via GLUT-1 expression through the PI3 kinase pathway. In an animal model of pancreatic cancer, 132 hamsters exposed to the carcinogen N-nitrosobis-(2-oxopropyl)amine and placed on a high-fat diet leading to hyperinsulinemia developed a high frequency of hyperplastic and malignant lesions. When pretreated with metformin to normalize insulin levels prior to carcinogen exposure, there was a marked reduction in lesions noted. As the authors noted, this lends support to the role of pancreatic islet insulin production and may explain the association between pancreatic cancer and obesity, usually associated with insulin resistance.
Breast Cancer
No malignancy better illustrates the complexity of insulin and IGF system effects on tumor development, as well as outcome, than breast carcinoma. This reflects in part the extensive research devoted to this disease. While the import of estrogen in breast cancer development and outcome has been long appreciated, particularly in the postmenopausal setting, the impact of hyperinsulinemia is increasingly recognized as playing an important role.
Obesity, particularly associated with weight gain from adolescence to middle age, is a well-established risk factor for postmenopausal breast cancer, 133 with traditional factors such as parity, age of menarche, and HRT use. Increasingly, it is also being recognized as important in breast cancer survival. The adverse impact of obesity at the time of diagnosis has been noted for many years. In the ACS Cancer Prevention II Study, following 424,168 women over 14 years, breast cancer mortality increased continually and significantly with increasing BMI. The adjustable risk attributable to overweight corresponded to approximately 30% to 50% of postmenopausal breast cancer death. 134 This, the largest prospective study to date, supports numerous previous trials 135, 136 but shows a substantially larger impact of BMI on survival. Obesity has also been associated in numerous studies with adverse features at diagnosis including larger tumor size, advanced grade, and increased nodal involvement. [137] [138] [139] While partly attributed by some to increased adiposerelated estrogen, this association has also been noted in both pre-and postmenopausal estrogen receptor (ER)-negative breast cancer patients. 139, 140 In a large, population-based, follow-up study from Fred Hutchinson Cancer Research Center 139 looking at breast cancer mortality in 1177 women younger than 45 years of age, women in the highest quartile of BMI had 2.5 times the risk of dying in 5 years, were more likely to be ER negative, and were more likely to have higher S phase and higher tumor grade reflecting higher cellular proliferation than tumors in thinner women. The authors speculated on the potential role of insulin in this association. Despite the well-known inverse relationship between weight and premenopausal breast carcinoma, it appears that those women who are overweight may develop a more aggressive tumor with ultimately poorer outcomes. Increased insulin and IGF signaling may provide the chronic proliferative stimulus leading to tumor progression and this adverse outcome.
Numerous other studies support the role of insulin. An important confounder in studies of BMI and breast cancer is body fat distribution. Women with an android or abdominal obesity pattern based on increased WHR, typical of the insulin-resistant state, appear be at higher risk than women with a normal adipose distribution. [139] [140] [141] A history of diabetes mellitus has been associated with both an increased risk and an increased mortality from breast cancer. 142, 143 In a large, case-control study from Italy, 144 a high glycemic load diet emerged as an important risk factor for breast cancer. In a study assessing both serum 145 and red blood cell 146 phospholipid fatty acid composition, increased oleic acid and decreased stearic acid content were associated with increased breast cancer risk. This was attributed to increased activity of delta 9desaturase enzyme activity, upregulated by insulin resistance. In a case-control study of 99 premeno-pausal women, controlling for weight, elevated serum insulin levels were significantly associated with breast cancer risk. 147 Similarly, free IGF-1 has been associated with an increased breast cancer risk . 148 Recent prospective studies have reinforced the potential direct effect of insulin on breast cancer outcome. In a large cohort of women with early-stage breast cancer, without known diabetes, fasting insulin levels were associated with both distant recurrence and death, controlling for tumor stage and traditional prognostic factors. 149 In a follow-up study of this same cohort 150 evaluating the IGF/IGFBP system, low levels of IGFBP-1 were correlated with increased insulin and associated with both obesity and diet. Low IGFBP-1 predicted distant recurrence and death, related to the effect of insulin on decreased IGFBP-1 gene expression.
Breast carcinoma cells highly express insulin receptors, IGF-1 receptors, and the hybrid insulin-IGF-1 receptor. [151] [152] [153] Breast cancer patients with increased BMI show a higher expression of IGF-1 receptor mRNA, accompanied by increased cyclin D1 expression. 154 There is important evidence demonstrating significant interactions between the insulin/IGF system and alternate growth receptor pathways, including the estrogen receptor and the EGF/HER-2/neu pathway. There is significant cross-talk between the ER and IGFR. Both estradiol and IGF-1 may synergistically activate the growth receptor signaling cascade, promoting cell cycle progression through expression of cyclins D and E. [155] [156] [157] In addition to its antiestrogenic effects, tamoxifen reduces IGF-1 and inhibits IRS signaling via PI3 kinase. 158, 159 In addition, in tamoxifenresistant cells, there is evidence that tamoxifen may actually stimulate cell proliferation via sensitization to the growth stimulatory effects of IGF-1. 160, 161 An intriguing report by Hyrniuk et al 162 indicates that postmenopausal breast cancer patients with diabetes mellitus do not respond to tamoxifen, suggesting the associated hyperinsulinemia may interfere with ER inhibition, perhaps by coactivating the insulin/IGF pathway.
There is additional evidence that increased IGF-1 signaling may inhibit cell death from chemotherapy. IGF-1 enhances survival of MCF-7 breast cancer cells after exposure to actinomycin-D, 5-fluorouracil, cisplatin, and adriamycin. 163 This appears to involve distinct mechanisms. IGF-1 rescue of adriamycininduced apoptosis involves PI3 kinase only while IGF-1 rescue of paclitaxel-induced apoptosis involves both PI3 kinase and MAP kinase. 164 Trastuzumab (herceptin), an anti-HER 2/neu receptor monoclonal antibody, is active against HER 2/neu + breast cancers. Increased IGF-1R signaling interferes with this action and may contribute to herceptin resistance. 165 Simultaneous blockade of IGF-1R signaling restores tumor sensitivity to herceptin. Similarly, IGF-1 appears to mediate resistance to anti-EGFR therapy in primary glioblastoma cells via PI3 kinase activation, 166 as well as interfering with radiationinduced apoptosis in a variety of cell lines. 167 Recent molecular studies have linked growth receptor signaling components with adverse outcomes in breast cancer. The cyclin-dependent kinase p27 is a putative tumor suppressor. After transit to the nucleus, p27 mediates cell cycle growth arrest. Recent studies 168, 169 demonstrate that PI3K-Akt inhibits growth arrest by phosphorylation of p27, preventing its transit from cytoplasm to nucleus. Furthermore, the presence of inactivated p27 correlated with poor prognosis and an aggressive phenotype in early-stage breast cancer. It is noteworthy that PI3K-Akt represents one of the dominant molecular pathways of insulin/IGF action.
A compelling model can be described that links the growing evidence of insulin to breast cancer outcome. Both through the direct effect of insulin and its indirect impact on increasing IGF-1R activation, increased growth factor pathway signaling may drive progression to a more aggressive, poorer prognosis tumor with shortened survival. In addition, antagonism by IGF-1 at the receptor level may interfere with a variety of interventions including hormone therapy, chemotherapy, and herceptin, potentially reducing response rates and further impairing outcomes in the presence of insulin resistance. The inflammatory state characteristic of insulin resistance may contribute additionally to tumor progression via cytokine-mediated angiogenesis, increased proliferative signaling, and so forth. This reflects a process previously noted in earlystage cancer, phenotypic modulation, during which paracrine and endocrine influences have the capacity to drive the progression from indolent to more aggressive malignancy. This also provides a window during which noncytotoxic interventions, including diet and exercise, may downregulate the hyperinsulinemic state and the accompanying increase in IGF-1, potentially altering outcomes and enhancing the efficacy of conventional anticancer therapies.
A recent concern is the growing evidence that adjuvant chemotherapy and hormone therapy of breast cancer may lead to weight gain in women [170] [171] [172] and that this weight gain has been associated with adverse outcomes, including increased risk of recurrence and lower survival. 173, 174 Trials of nutrition counseling and exercise 175 are in progress to address this concern. There remains uncertainty about the exact mechanism, although reduced activity, increased caloric intake, and metabolic changes may play a role. [176] [177] [178] We are currently embarking on a pilot study to determine if women who undergo adjuvant therapy are at risk for developing insulin resistance as a consequence of treatment-related weight gain, as an explanation for these adverse outcomes.
Stress and the Insulin-Cancer Connection
The role of stress in cancer causation and prognosis has been of particular concern to the integrative cancer practitioner and accepted by much of the lay public as an important and indisputable association. In contrast, the research on the role of stress in both cancer etiology and progression has been controversial. In striking contrast to patients' views, many in the conventional cancer community dismiss any effect on outcome as unlikely while acknowledging the effect of stress on quality of life. In addition to understandable concerns about enhancing guilt and generating stress in cancer patients who may be unable to muster the "right attitude," this also reflects a failure to appreciate the potential mechanisms through which stress may alter tumor biology.
While stress, as understood by the public, is ubiquitous and loses much of its explanatory role, certain psychological attributes, reflecting coping styles in the face of illness and often accompanied by evidence of anxiety and depression on standard testing, have been associated with cancer prognosis. In a recent and provocative study, Watson and others 179 assessed response to illness using the Mental Adjustment to Cancer Scale, the Courtald emotional control scale, and the Hospital Anxiety and Depression (HAD) Scale in 500 women with early-stage breast cancer and its effect on relapse and survival. With more than 5 years of followup, women with a high score on depression on the HAD Scale had an increased mortality from any cause, including breast cancer. In addition, women with a high level of helplessness and hopelessness had a significantly higher risk of relapse or death from breast cancer. However, a "fighting spirit" or denial style of coping did not have any impact. This study suggests the potentially powerful effect of negative attitudes and coping style on survival. In a provocative study from the University of Hull, UK, in women with locally advanced breast cancer necessitating preoperative neoadjuvant chemotherapy, measures of increased depression and anxiety on the HAD Scale preceding treatment were significant and independent predictors of pathologic and clinical response to chemotherapy. 180 In contrast to the cancer setting, the role of depression and anxiety on outcomes after myocardial infarct and coronary bypass surgery has become well accepted in the cardiology community. Unfortunately, oncologists have been shown to be very adept at recognizing physical complaints among their patients but less skilled at identifying depression or anxiety. In one study, 181 oncologists were aware of the physical complaints in 80% of their patients but failed to recognize clinical anxiety in 83% and clinical depression in 94% of affected patients. This reflects both inadequate training and the lesser importance placed on psychosocial stress by the medical oncology community as a target for intervention.
An important part of complementary therapies in breast cancer has been support groups. The classic study by Spiegel et al 182 using supportive-expressive group psychotherapy in women with metastatic breast cancer, unexpectedly demonstrated a marked improvement in survival. Similar effects have been noted in melanoma. 183 A recent multicenter trial replicating the original methodology failed to show an effect on breast cancer survival. The contrasting results may reflect the growing availability of family and community support since the original Spiegel study, calling into question the ability to have a true control group. It is also likely that only a small subset of patients have a helpless and hopeless response to their illness, portending a poor outcome. Small trials may easily miss this subpopulation.
An additional difficulty in trials on stress is the importance of a physiologic measure that accurately predicts stress in patients. There is growing recognition of the neurohumoral mediators of stress, acting through the HPA pathway. 52 Chronic stress, as defined by helplessness in animal models, has been long known to affect the HPA axis, leading to adverse physiologic consequences, particularly on immune function. Recent studies have examined the effect of an abnormal diurnal cortisol pattern as a measure of HPA dysfunction. Sephton and others 184 measured diurnal salivary cortisol patterns in women with metastatic breast cancer. Those with an abnormal, flattened cortisol rhythm were found to have shortened survival. This pattern was associated with a reduction in circulating NK cell number and activity. Similarly, in a study of 200 colon cancer patients, survival at 4 years was markedly reduced in those with a dampened diurnal cortisol rhythm. 185 Much of the research on mind-body interventions, including support-group interventions, noted above has focused on their effect on cellular immune function as an explanation for improved outcomes. As noted, the immune effects of abnormal HPA axis functioning have been well demonstrated. Unfortunately, there is surprisingly little support for this wellaccepted hypothesis. The HIV epidemic, associated with profound T-lymphocyte immunodeficiency, has been linked to a very specific subset of malignancies, those associated with known virally mediated oncogenesis (Kaposi's sarcoma with herpes virus-8, squamous carcinomas of the cervix and anogenital region with human papilloma virus, and high-grade lymphomas with Epstein-Barr virus). Interestingly, on an age-adjusted basis, HIV-infected patients appear to be at a lower risk for common epithelial cancers, including breast, colon, and prostate. 186 Levine and others 187 have reported that HIV patients with lowgrade lymphomas have the same natural history and long-term survival as the non-HIV population. Thus, it appears the major effect of this profound immunodeficiency state is the failure to recognize virally transformed cells but has little impact on incidence or outcomes in most common cancers. Limited studies on NK cell deficiency 188 also imply predominant risk for increased viral infections rather than malignancy.
Immune interventions to enhance intrinsic immune function such as interferons have a limited spectrum of efficacy, including melanoma, renal cell cancer, and lymphomas. Interestingly, these are also the cancers for which adoptive therapy with lymphokineactivated killer cell/IL-2 therapies have shown activity, albeit to a limited degree. 189 The presence of immune infiltrates within tumors have been inconsistently associated with prognosis, and recent studies in lung and breast cancer suggest an adverse rather than favorable prognostic impact, in part mediated by lymphokinerelated angiogenesis factors and partly the result of a direct CD4, CD25 T-cell-mediated suppression of antitumor immune response. Thus, while being a widely accepted paradigm by the public and both conventional and alternative cancer practitioners, there is surprisingly little support for a role for intrinsic immune function and approaches that alter levels of patients' immune effector cells on outcomes of most cancers. This contrasts with recent research using approaches such as monoclonal antibody treatment and dendritic cell vaccines that depend on targeting growth receptors with ex vivo generated antibodies or manipulating the antigen/APC/effector cell relationship.
An alternative explanation for the role of stress and cancer outcomes and etiology as well as the relationship between altered HPA axis function and cancer prognosis is the insulin/IGF system. Evidence that cortisol is linked to insulin resistance is well known. Cushing syndrome, associated with endogenous hypercortisolism, is characterized by abdominal/ visceral obesity and insulin resistance. Similarly, infusions of cortisol to levels seen in severe stress will result in impaired insulin sensitivity. 190 In the Zucker rat model, 191 immobilization stress results in increased cortisol levels, secondary hyperinsulinemia, and weight gain unrelated to caloric expenditure or intake.
Increasing evidence links psychosocial stress to both insulin resistance and the development of central (abdominal/visceral) obesity in humans. Acute stress provoked by disturbing visual images has been shown to impair insulin sensitivity. 192 Studies have linked increased environmental stress with increased WHR, associated with dysregulation of the HPA axis and features of the metabolic syndrome. 193, 194 The syndrome of severe depression with secondary hypercorticolism is associated with increased visceral obesity and insulin resistance. Bjorntorp and others 194 have called attention to the central mechanism, involving hypothalamic pathways, mediating the association between chronic stress, increasing visceral obesity, and the development of the metabolic syndrome. The recent evidence for increased measures of inflammation in chronic depression appears also to be mediated by this association. 84, 85 Interestingly, evidence for genetic predisposition to insulin resistance has been linked to polymorphisms in the glucocorticoid receptor present in the central nervous system as well as in high levels within visceral adipose cells, and a central, hypothalamic mechanism has been proposed for the origins of insulin resistance and diabetes mellitus. 193, 194 This centrally mediated stress response with both increased insulin resistance and an increased inflammatory state have been linked to an increased oxidative state, 195 aging, 196 and increased cardiovascular risk. 197 The well-documented links between hyperinsulinemia and both cancer etiology and prognosis provide the most biologically plausible explanation to date for the relationship between stress and cancer outcomes.
Implications of the Obesity-Insulin-Cancer Connections
That insulin and the IGF system play such a central role in cancer should not be surprising from an evolutionary perspective. Growing evidence exists for the role of early caloric restriction and increasing longevity, associated with a reduced incidence of spontaneous tumors. This appears to be, in part, mediated by the IGF system. 198 In Caenorhabditis elegans, an invertebrate organism favored by molecular and neurobiologists, the homologue of the IGF-1R (DAF gene) appears linked to aging. 199 When mutated, survival is prolonged by 30% to 40% above normal life span. Throughout human evolution, caloric intake was more limited, accompanied by greater nutrient diversity and unpredictablity of food sources. Indeed, the risk of diabetes in modern populations has been attributed to the "thrifty phenotype," accompanied by an increased insulin response in the face of caloric abundance, to allow for increased adipose stores, available for energy during frequent, often seasonal times of paucity. 200 In the face of abundant, year-round, high-calorie diets, with calorie-dense, nutrient-poor foods typical of Western societies, increased obesity and diabetes are inevitable consequences. This is now evident in underdeveloped countries undergoing transition to more Western lifestyles.
Of interest is the growing recognition of early childhood and even prenatal influences on the development of adult obesity and the metabolic syndrome. Children born at low weight for gestational age, secondary to intrauterine growth retardation, have a higher risk of adult obesity as well as diabetes mellitus and cardiovascular disease. 201, 202 Recent research indicates that malnutrition in the first year of life as well increases the risk of insulin resistance and glucose intolerance in early adulthood, an effect worsened by increasing body mass. 203 Thus, while early caloric restriction is suggested to alter long-term survival, attention to the adequacy of maternal and infant nutrition is likely of equal importance in altering the risk of adult obesity, insulin resistance, and the attendant risk of chronic illness such as cancer and heart disease.
That immunity should have limited impact should also not be surprising. Evolution has fashioned an effective immune response to allow for control of infectious disease, viral, bacterial, and mycobacterial, typically of greatest survival threat to premodern populations. In fact, there is little selection pressure favoring an effective immune surveillance mechanism for epithelial cancers, affecting predominantly postreproductive age groups. There are, in fact, more likely to be important safeguards against antitumor immunity, both to avoid risk of autoimmune disease and allow for senescence necessary for the survival of any species with limited resources. Indeed, there is recent evidence that a selective increase in a subpopulation of regulator T cells (CD4+, CD25+) are found infiltrating tumors 204 or circulating peripherally in patients with malignancy. 205 This finding correlates with tumor progression and a poorer prognosis. This unique Tcell population is crucial in maintaining immune tolerance and limiting autoimmune disease. Ironically, it also appears to actively limit or prevent any immune response to many malignancies.
For both the conventional and integrative practitioner, this association has numerous implications. Obesity, particularly with an abdominal-visceral component, must be considered an important target for intervention, both epidemiologically to reduce cancer risk in populations and as an important adjunct during treatment of individual patients with cancer. The triad of diet and nutrition, exercise, and stress reduction form the foundation of this approach. Integrative practitioners have long placed an emphasis on these modalities, and the insulin-cancer hypothesis provides crucial validation for these interventions in the care of every cancer patient. We are now past the time when a typical physician's response to the cancer patient's query about diet, "Eat whatever you want, just keep your weight up," is acceptable. In addition to dietary counseling designed to limit weight and insulin resistance, the use of selected supplements such as alpha-lipoic acid, chromium, omega-3 fats, and interesting herbal compounds (Gymnema sylvestre) may play a role in increasing insulin sensitivity alongside conventional pharmaceuticals such as the thiazolidinediones.
The recognition that exercise increases insulin sensitivity and reduces the effect of obesity in cancer should provide motivation for an exercise prescription as a necessary part of cancer care. Indeed, the benefits of exercise extend beyond its role in reducing insulin resistance to increased tolerance of conventional chemotherapy, 206 reduced treatment-related fatigue, 207 and decreased depression and anxiety. 208 The central role of stress reduction is crucial, particularly with evidence that ongoing severe stress can lead to insulin resistance in the face of diet and activity levels that would otherwise be protective. Every patient needs careful assessment for their psychological response to their illness and should be provided with options for both conventional and integrative approaches that are individualized for their needs. Importantly, the crucial connection between insulin and cancer outcomes should provide a greater awareness of the need to adequately reimburse for these important interventions.
Of great interest is the well-known phenomenon of hyperglycemia and insulin resistance as a typical metabolic response to advanced cancer. This metabolic profile has been well documented and is noted in every standard oncology textbook. 209, 210 Despite this well-known phenomenon, there has been little attention paid to this as an important target for intervention. Limited data from our group with advanced pancreatic cancer patients have demonstrated that limiting the associated insulin resistance may improve outcomes and potentially increase tumor response to conventional chemotherapy. In the future, larger trials of combinations of conventional treatments combined with a comprehensive integrative care approach targeting the insulin-resistant state will help to answer these crucial questions.
